Detection of aberrant p16 methylation in the plasma and serum of liver cancer patients
Publication in refereed journal


全文

引用次數

其它資訊
摘要We have studied the feasibility of detecting tumor-associated aberrant p16 methylation in the circulation of patients with hepatocellular carcinoma (HCC). We extracted DNA from the tumor tissues and peripheral blood plasma or serum of 22 HCC patients, p16 methylation was found in 73% (16 of 22) of HCC tissues using methylation-specific PCR, Among the 16 cases with aberrant methylation in the tumor tissues, similar changes were also detected in the plasma/serum samples of 81% (13 of 16) of the cases. No methylated p16 sequences were detected in the peripheral plasma/serum of the six HCC cases without these changes in the tumor, in 38 patients with chronic hepatitis/cirrhosis, or in 10 healthy control subjects. These results suggest that circulating liver tumor DNA may be detected using tumor-associated DNA methylation changes. Because methylation abnormalities have been found in many other genes and tumor types, this approach may have implications for the noninvasive detection of a wide variety of cancers.
著者Wong IHN, Lo YMD, Zhang J, Liew CT, Ng MHL, Wong N, Lai PBS, Lau WY, Hjelm NM, Johnson PJ
期刊名稱Cancer Research
出版年份1999
月份1
日期1
卷號59
期次1
出版社AMER ASSOC CANCER RESEARCH
頁次71 - 73
國際標準期刊號0008-5472
電子國際標準期刊號1538-7445
語言英式英語
Web of Science 學科類別Oncology; ONCOLOGY

上次更新時間 2021-18-09 於 00:35